Product Description
CC-95775 is a novel oral small molecule bromodomain inhibitor. It is a non-specific inhibitor with potent activity against all 4 BET family members (BRD2, BRD3, BRD4, BRDT), and shows additional activity towards several non-BET bromodomain proteins. (Sourced from: https://aacrjournals.org/mct/article/20/12_Supplement/P033/675915/Abstract-P033-CC-95775-a-reversible-oral)
Mechanisms of Action: BET Inhibitor, BRD4 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04089527 |
CC-95775-ST-001 | P1 |
Completed |
Lymphoma, Non-Hodgkin |
2021-10-25 |
31% |
2022-02-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/14/2021 |
News Article |
Bromodomain Testis Specific Protein Drug Development Research Report 2021 - ResearchAndMarkets.com |
|
01/30/2020 |
News Article |
FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb |
|
11/06/2019 |
News Article |
FORMA Announces Oral and Poster Presentations at Upcoming 2019 ASH Annual Meeting |